NVTR - Nuvectra Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.7100
-0.2400 (-6.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.9500
Open3.9300
Bid0.0000 x 1800
Ask0.0000 x 1000
Day's Range3.6300 - 4.1300
52 Week Range3.4800 - 25.1700
Volume505,008
Avg. Volume305,126
Market Cap66.039M
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-3.2540
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Nuvectra® to Participate in Two Upcoming Investor Conferences

    PLANO, Texas, June 12, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that members of management are scheduled to.

  • GlobeNewswire6 days ago

    Nuvectra Files Regulatory Submission with FDA for Algovita® Full-Body MR-Conditional Approval

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today that it has filed its regulatory submission with the U.S. Food and Drug Administration (FDA) for full-body MR-conditional approval for the Company’s Algovita SCS system. Fred Parks, Chief Executive Officer, commented, “We believe full-body MR-conditional approval in the United States, in addition to Algovita’s full-body MR-conditional CE Mark approval, will supplement our existing competitive advantages and expand the number of eligible patients. This submission, pending regulatory approval from the FDA, would position the Company to achieve MR-conditional approval at or around year end 2019 following a 180-day review process.

  • Penny Stocks to Watch for June 2019
    Investopedia18 days ago

    Penny Stocks to Watch for June 2019

    While the markets may be due for a correction, penny stock opportunities abound for investors who know how to do their due diligence.

  • GlobeNewswire18 days ago

    Nuvectra Highlights Positive Preliminary Algovita® Clinical Data at the INS 14th Annual World Congress

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, announced today preliminary Algovita® clinical data from its U.S. and EU multi-center, single-arm study demonstrating lead fracture and migration rates that were below industry average. The study data was presented by Robert Levy, MD, PhD, a board-certified neurological surgeon and member of Nuvectra’s Medical Advisory Board, at the International Neuromodulation Society (INS) 14th Annual World Congress in Sydney, Australia. The preliminary results are based on clinical outcomes for 75 patients up to approximately 7 months following permanent implantation at 18 clinical sites.

  • Have Insiders Been Buying Nuvectra Corporation (NASDAQ:NVTR) Shares?
    Simply Wall St.25 days ago

    Have Insiders Been Buying Nuvectra Corporation (NASDAQ:NVTR) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • GlobeNewswirelast month

    Nuvectra® Announces Departure of COO & CFO Walter Z. Berger

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced that Walter Z. Berger has resigned as Nuvectra’s Chief Operating Officer and Chief Financial Officer to pursue another business opportunity, effective May 24, 2019. The Board of Directors accepted Mr. Berger’s resignation and has appointed Ms. Jennifer Kosharek, the Company’s current Vice President, Controller and Principal Accounting Officer, as interim Chief Financial Officer as it initiates a search for a successor.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of NVTR earnings conference call or presentation 1-May-19 8:30pm GMT

    Q1 2019 Nuvectra Corp Earnings Call

  • Nuvectra Corporation Common Stock (NVTR) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Nuvectra Corporation Common Stock (NVTR) Q1 2019 Earnings Call Transcript

    NVTR earnings call for the period ending March 31, 2019.

  • Nuvectra (NVTR) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Nuvectra (NVTR) Reports Q1 Loss, Misses Revenue Estimates

    Nuvectra (NVTR) delivered earnings and revenue surprises of -27.69% and -12.79%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Nuvectra: 1Q Earnings Snapshot

    The Plano, Texas-based company said it had a loss of 83 cents per share. The medical device company posted revenue of $11.1 million in the period, which did not meet Street forecasts. Three analysts surveyed ...

  • GlobeNewswire2 months ago

    Nuvectra® Reports First Quarter 2019 Financial Results

    PLANO, Texas, May 01, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended.

  • ACCESSWIRE2 months ago

    Nuvectra Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Nuvectra Corp. (NASDAQ: NVTR ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 1, 2019 at 4:30 PM Eastern Time. ...

  • Nuvectra (NVTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks2 months ago

    Nuvectra (NVTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    Nuvectra to Report First Quarter 2019 Financial Results on May 1, 2019

    PLANO, Texas, April 22, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for.

  • Are Nuvectra Corporation (NASDAQ:NVTR) Shareholders Getting A Good Deal?
    Simply Wall St.2 months ago

    Are Nuvectra Corporation (NASDAQ:NVTR) Shareholders Getting A Good Deal?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Nuvectra Corporation (NASDAQ:NVTR) shareholders, and potential investors, need to understand how much cash the business makes...

  • ACCESSWIRE2 months ago

    FDA Events Can Send Stocks Soaring: Here's One That No One Is Talking About

    Biogen's (BIIG) latest clinical trial failure is a testament to the difficulty in developing drugs for Alzheimer's, which is littered with failures in the last ten years. But other neurology fields have ...

  • GlobeNewswire3 months ago

    Nuvectra® Appoints Anthony P. Bihl, III as New Chairman of the Board

    Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced the appointment of Anthony P. Bihl, III as Chairman of the Board of Directors, following Dr. Joseph A. Miller’s retirement from the Board, effective immediately. Concurrently, Jane J. Song was appointed as an independent member of the Company’s Board of Directors and as a member of the Board’s Governance and Nomination Committee. Mr. Bihl stated, “I am honored to enter my new role as Chairman of the Board and welcome Jane, an industry leader, to Nuvectra.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of NVTR earnings conference call or presentation 28-Feb-19 9:30pm GMT

    Q4 2018 Nuvectra Corp Earnings Call

  • GuruFocus.com3 months ago

    Nuvectra Corp (NVTR) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Nuvectra Corp (NASDAQ:NVTR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.

  • GlobeNewswire4 months ago

    Nuvectra® Reports Fourth Quarter and Full Year 2018 Financial Results

    PLANO, Texas, Feb. 28, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full.

  • How Financially Strong Is Nuvectra Corporation (NASDAQ:NVTR)?
    Simply Wall St.4 months ago

    How Financially Strong Is Nuvectra Corporation (NASDAQ:NVTR)?

    While small-cap stocks, such as Nuvectra Corporation (NASDAQ:NVTR) with its market cap of US$246m, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • GlobeNewswire4 months ago

    Nuvectra® to Present at 39th Annual Cowen Healthcare Conference

    PLANO, Texas, Feb. 26, 2019 -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Fred Parks, PhD, Chief Executive Officer,.

  • Will Nuvectra (NVTR) Report Negative Earnings Next Week? What You Should Know
    Zacks4 months ago

    Will Nuvectra (NVTR) Report Negative Earnings Next Week? What You Should Know

    Nuvectra (NVTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire4 months ago

    The Future Is Now; Med Tech That’s Changing Lives

    Investorideas.com, a leading investor news resource covering medical technology and healthcare stocks releases a snapshot looking at the rapid advancements happening in the med tech sector and how many of these “far off” projects are now on the verge of reality. BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, recently announced that the Company successfully conducted the first patient cases using PURE EP™ System, its FDA approved proprietary signal acquisition and processing technology. The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX.